Roche, Actavis Ink Deal on Three Products

Swiss drugmaker Roche and Iceland’s Actavis announced that they have signed agreements for Roche’s sale of three pharmaceutical products to Actavis.

All product rights — with some territorial exceptions — for Bezalip and Rapilysin, both used in the cardiovascular field, and for the dermatology product Neotigason are being transferred to Actavis, the companies said.

The transactions are expected to close in stages later this year and in early 2008, the companies added.

The companies did not disclose financial terms.